These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 25716362)

  • 1. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma.
    Korfel A; Thiel E; Martus P; Möhle R; Griesinger F; Rauch M; Röth A; Hertenstein B; Fischer T; Hundsberger T; Mergenthaler HG; Junghanß C; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Roth P; Bamberg M; Pietsch T; Weller M
    Neurology; 2015 Mar; 84(12):1242-8. PubMed ID: 25716362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
    Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
    J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
    Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
    Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
    Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
    Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
    J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years.
    Ferreri AJ; Ciceri F; Brandes AA; Montanari M; Balzarotti M; Spina M; Ilariucci F; Zaja F; Stelitano C; Bobbio F; Corazzelli G; Baldini L; Reni M
    Neurology; 2014 Apr; 82(15):1370-3. PubMed ID: 24634458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of additional radiotherapy for primary central nervous system lymphoma.
    Zacher J; Kasenda B; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009211. PubMed ID: 24931518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
    Shah GD; Yahalom J; Correa DD; Lai RK; Raizer JJ; Schiff D; LaRocca R; Grant B; DeAngelis LM; Abrey LE
    J Clin Oncol; 2007 Oct; 25(30):4730-5. PubMed ID: 17947720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51.
    Laack NN; Ballman KV; Brown PB; O'Neill BP;
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1429-39. PubMed ID: 16863926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group).
    O'Brien PC; Roos DE; Pratt G; Liew KH; Barton MB; Poulsen MG; Olver IN; Trotter GE;
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):408-13. PubMed ID: 16198065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of treatment of 112 cases of primary CNS lymphoma.
    Yamanaka R; Morii K; Shinbo Y; Homma J; Sano M; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Kakuma T; Tanaka R
    Jpn J Clin Oncol; 2008 May; 38(5):373-80. PubMed ID: 18413337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
    Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T
    Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.
    Roth P; Martus P; Kiewe P; Möhle R; Klasen H; Rauch M; Röth A; Kaun S; Thiel E; Korfel A; Weller M
    Neurology; 2012 Aug; 79(9):890-6. PubMed ID: 22895585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
    Kiewe P; Fischer L; Martus P; Thiel E; Korfel A
    Cancer; 2008 Apr; 112(8):1812-20. PubMed ID: 18318432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial.
    Kreher S; Strehlow F; Martus P; Roth P; Hertenstein B; Röth A; Birnbaum T; Griesinger F; Rauch M; Kanz L; Thiel E; Weller M; Korfel A
    Ann Hematol; 2015 Mar; 94(3):409-14. PubMed ID: 25217230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How important is whole brain radiotherapy for treatment of primary CNS lymphoma?
    Cabanillas F
    Lancet Oncol; 2010 Nov; 11(11):1011-2. PubMed ID: 20970379
    [No Abstract]   [Full Text] [Related]  

  • 19. Rituximab with high-dose methotrexate in primary central nervous system lymphoma.
    Kansara R; Shenkier TN; Connors JM; Sehn LH; Savage KJ; Gerrie AS; Villa D
    Am J Hematol; 2015 Dec; 90(12):1149-54. PubMed ID: 26414492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary central nervous system lymphoma: a single-centre experience of 55 unselected cases.
    Hodson DJ; Bowles KM; Cooke LJ; Kläger SL; Powell GA; Laing RJ; Grant JW; Williams MV; Burnet NG; Marcus RE
    Clin Oncol (R Coll Radiol); 2005 May; 17(3):185-91. PubMed ID: 15901003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.